KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Liao, Wenting, Overman, Michael J., Boutin, Adam T., Shang, Xiaoying, Zhao, Di, Dey, Prasenjit, Li, Jiexi, Wang, Guocan +19 more·2019·Cancer Cell
DOI 10.1016/j.ccell.2019.02.008

Cited by (619)

Items 101–200 of 619

  1. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma
    Chaoqi Zhang, Zhen Zhang, Guochao Zhang, Zhihui Zhang, Yuejun Luo, Feng Wang, Sihui Wang, Yun Che, Qingpeng Zeng, Nan Sun et al. · 2020 · Cancer Letters
  2. Relevance of Regulatory T Cells during Colorectal Cancer Development
    Jonadab E. Olguín, Itzel Medina-Andrade, Tonathiu Rodríguez, Miriam Rodríguez‐Sosa, Luis Ignacio Terrazas · 2020 · Cancers
  3. Rational targeting of immunosuppressive neutrophils in cancer
    Yun Zhao, Sharif Rahmy, Zhongmin Liu, Chao Zhang, Xin Lü · 2020 · Pharmacology & Therapeutics
  4. Elimination of oncogenic Kras in genetic mouse models eradicates pancreatic cancer by inducing Fas-dependent apoptosis by CD8+ T cells
    K. Mahadevan, V. LeBleu, E. V. Ramirez, Yang Chen, Bing-Rui Li, Amari M. Sockwell, M. Gagea, H. Sugimoto, Lakshmi Kavitha Sthanam, D. Tampe et al. · 2023 · Developmental Cell
  5. The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control
    Jinhai Deng, Teng Pan, Zaoqu Liu, Caitlin McCarthy, Jose Miguel Vicencio, Lulu Cao, Giovanna Alfano, Ali Abdulnabi Suwaidan, Mingzhu Yin, Richard Beatson et al. · 2023 · British Journal of Cancer
  6. MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
    Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, Laura Soucek · 2024 · Signal Transduction and Targeted Therapy
  7. Prediction of biomarkers and therapeutic combinations for anti-PD-1 immunotherapy using the global gene network association
    Chia-Chin Wu, Yanru Wang, John Andrew Livingston, Jianhua Zhang, P. Andrew Futreal · 2022 · Nature Communications
  8. KIAA1199 drives immune suppression to promote colorectal cancer liver metastasis by modulating neutrophil infiltration
    Haihong Wang, Biying Zhang, Ruiqi Li, Jiayuan Chen, Guojie Xu, Ying Zhu, Jiao Li, Qing Duo Liang, Qingling Hua, Lanqing Wang et al. · 2022 · Hepatology
  9. Precision therapy in RAS mutant colorectal cancer
    Dienstmann, Rodrigo, Connor, Kate, Byrne, Annette T., Fridman, W.H., Lambrechts, D., Sadanandam, A., Trusolino, L., Prehn, J.H.M., Tabernero, J., Kolch, W. · 2020 · Gastroenterology
  10. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma
    Gao, Ge, Liao, Weiting, Ma, Qizhi, Zhang, Benxia, Chen, Yue, Wang, Yongsheng · 2020 · Lung Cancer
  11. Drugging the Undruggable: Advances on RAS Targeting in Cancer
    Míriam Molina‐Arcas, Amit Samani, Julian Downward · 2021 · Genes
  12. Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer
    Yufei Wang, Anna Jia, Yujing Bi, Yuexin Wang, Guangwei Liu · 2020 · Cells
  13. Targeting KRAS: The Elephant in the Room of Epithelial Cancers
    Valeria Merz, Marina Gaule, Camilla Zecchetto, Alessandro Cavaliere, Simona Casalino, Camilla Pesoni, Serena Contarelli, Fabio Sabbadini, Monica Bertolini, Domenico Mangiameli et al. · 2021 · Frontiers in Oncology
  14. The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
    Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi · 2024 · Lung Cancer
  15. Therapeutic Targeting of the Colorectal Tumor Stroma
    Wolf H. Fridman, Ian S. Miller, Catherine Sautès‐Fridman, Annette T. Byrne · 2019 · Gastroenterology
  16. Green Tea Polyphenol EGCG Attenuates MDSCs-mediated Immunosuppression through Canonical and Non-Canonical Pathways in a 4T1 Murine Breast Cancer Model
    Ping Xu, Feng Yan, Yueling Zhao, Xiangbo Chen, Shili Sun, Yuefei Wang, Le Ying · 2020 · Nutrients
  17. Advances in colon cancer research: in vitro and animal models
    Tamsin R.M. Lannagan, René Jackstadt, Simon John Leedham, Owen James Sansom · 2021 · Current Opinion in Genetics & Development
  18. IGF1-mediated HOXA13 overexpression promotes colorectal cancer metastasis through upregulating ACLY and IGF1R
    Chenyang Qiao, Wenjie Huang, Jie Chen, Weibo Feng, Tongyue Zhang, Yijun Wang, Danfei Liu, Xiaoyu Ji, Meng Xie, Mengyu Sun et al. · 2021 · Cell Death and Disease
  19. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis
    Chenglin Qi, Mao‐Ling Huang, You Zou, Rui Yang, Yang Jiang, Jianfei Sheng, Yonggang Kong, Zezhang Tao, Hongyan Feng, Qingquan Hua et al. · 2021 · Journal of Experimental & Clinical Cancer Research
  20. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers
    Vito Amodio, Gianluca Mauri, Nicole Megan Reilly, Andrea Sartore Bianchi, Salvatore Siena, Alberto Bardelli, Giovanni Germano · 2021 · Cancers
  21. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy
    Xueyan Li, Jiahui Zhong, Xue Deng, Xuan Guo, Yantong Lu, Juze Lin, Xuhui Huang, Changjun Wang · 2021 · Frontiers in Immunology
  22. Prognostic Value of KRAS Mutations in Colorectal Cancer Patients
    Koulouridi, Asimina, Karagianni, Michaela, Messaritakis, Ippokratis, Sfakianaki, Maria, Voutsina, Alexandra, Trypaki, Maria, Bachlitzanaki, Maria, Koustas, Evangelos, Karamouzis, Michalis V., Ntavatzikos, Anastasios et al. · 2022 · Cancers
  23. Integrating Immunotherapy and Targeted Therapy in Cancer Treatment: Mechanistic Insights and Clinical Implications
    Johann S. Bergholz, Qiwei Wang, Sheheryar Kairas Kabraji, Jean J. Zhao · 2020 · Clinical Cancer Research
  24. Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
    Yufei Wang, Anna Jia, Yujing Bi, Yuexin Wang, Qiuli Yang, Yejin Cao, Yan Li, Guangwei Liu · 2020 · Cancers
  25. Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
    Anne-Laure Désage, Camille Léonce, Aurélie Swalduz, Sandra Ortiz‐Cuaran · 2022 · Frontiers in Oncology
  26. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer
    Iosune Baraibar, Oriol Mirallas, Nadia Saoudi Gonzalez, Javier Ros, Francesc Salvà, Josep M. Tabernero, Elena Élez · 2021 · Cancers
  27. Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
    Qiming Zhou, Yao Peng, Fenfen Ji, Huarong Chen, Wei Kang, Lam-Shing Chan, Hongyan Gou, Yufeng Lin, Pingmei Huang, Danyu Chen et al. · 2023 · Nature Communications
  28. Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC -Mutated Colorectal Cancer
    Rumi Lee, Jiexi Li, Jun Li, Chang‐Jiun Wu, Shan Jiang, Wen-Hao Hsu, Deepavali Chakravarti, Peiwen Chen, Kyle A. LaBella, Jing Li et al. · 2022 · Cancer Discovery
  29. Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link
    Vahid Khaze, Saeed Noorolyai, Mahya Ahmadpour Youshanlui, Saeidi Hossein, Hadi Nasiri, Behzad Mansoori, Uffe Holmskov, Behzad Baradaran · 2024 · International Journal of Colorectal Disease
  30. Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy
    Saud Almawash · 2025 · Cancers
  31. Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge
    Federica Marmorino, Alessandra Boccaccino, Marco Maria Germani, Alfredo Falcone, Chiara Cremolini · 2020 · Cancers
  32. MEK Inhibition Remodels the Immune Landscape of Mutant <i>KRAS</i> Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
    Yang, Bin, Li, Xi, Fu, Yu, Guo, Ensong, Ye, Youqiong, Li, Fuxia, Liu, Si, Xiao, Rourou, Liu, Chen, Lu, Funian et al. · 2021 · Cancer Research
  33. Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era
    Eduard Porta‐Pardo, Alfonso Valencia, Adam Godzik · 2020 · FEBS Letters
  34. GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
    DeNardo, David G, Galkin, Anna, Dupont, Jakob, Zhou, Lei, Bendell, Johanna · 2021 · Journal for ImmunoTherapy of Cancer
  35. Advances in mRNA-Based Cancer Vaccines
    Ling Ni · 2023 · Vaccines
  36. A review of antibody-based therapeutics targeting G protein-coupled receptors: an update
    Catherine J. Hutchings · 2020 · Expert Opinion on Biological Therapy
  37. Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach
    Hiroyuki Yamamoto, Yoshiyuki Watanabe, Tadateru Maehata, Kohzoh Imai, Fumio Itoh · 2020 · Archives of Toxicology
  38. Integrated multi-omics characterization of KRAS mutant colorectal cancer
    Wei Chong, Xingyu Zhu, Huicheng Ren, Chunshui Ye, Kang Xu, Zhe Wang, Shengtao Jia, Liang Shang, Leping Li, Hao Chen · 2022 · Theranostics
  39. The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies
    Qingzhe Wang, Min Yu, Shuang Zhang · 2025 · Frontiers in Immunology
  40. Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma
    Naoshi Nishida · 2021 · Cancers
  41. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression
    McCubrey, James A., Yang, Li V., Abrams, Stephen L., Steelman, Linda S., Follo, Matilde Y., Cocco, Lucio, Ratti, Stefano, Martelli, Alberto M., Augello, Giuseppa, Cervello, Melchiorre · 2022 · Cells
  42. Unraveling resistance to immunotherapy in MSI-high colorectal cancer
    Heregger, Ronald, Huemer, Florian, Steiner, Markus, Gonzalez-Martinez, Alejandra, Greil, Richard, Weiss, Lukas · 2023 · Cancers
  43. Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells
    Guohui Qin, Shasha Liu, Jinyan Liu, Hongwei Hu, Yang Li, Qitai Zhao, Congcong Li, Bin Zhang, Yi Zhang · 2023 · Signal Transduction and Targeted Therapy
  44. Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
    Anwaar Saeed, Robin Park, Harsh B. Pathak, Ayah Nedal Al-Bzour, Junqiang Dai, Milind A. Phadnis, Raed Moh’d Taiseer Al-Rajabi, Anup Kasi, Joaquina Celebre Baranda, Weijing Sun et al. · 2024 · Nature Communications
  45. Emerging Targets in Non-Small Cell Lung Cancer
    Louisa Liu, Joshua Soler, Karen L. Reckamp, K. Nathan Sankar · 2024 · International Journal of Molecular Sciences
  46. Serrated Colorectal Cancer: The Road Less Travelled?
    Yuki Nakanishi, Maria Teresa Díaz-Meco, Jorge Moscat · 2019 · Trends in cancer
  47. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
    Thomas Yul Avery, Natalie Köhler, Robert Zeiser, Tilman Brummer, Dietrich Alexander Ruess · 2022 · Frontiers in Oncology
  48. Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance
    Daiyong Deng, Riya H. Patel, Cheng-Yao Chiang, Pingping Hou · 2022 · Cells
  49. TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer
    Wen-Long Ye, Long Huang, Xiaoqin Yang, Shan Wan, Wen-Juan Gan, Yun Yang, Xiaoshun He, Feng Liu, Xin Guo, Yi-Xuan Liu et al. · 2024 · Proceedings of the National Academy of Sciences
  50. Inflammation and cancer: molecular mechanisms and clinical consequences
    Hikmet Akkız, Halis Şimşek, Deniz Balcı, Yakup Ülger, Engin Onan, Nevin Akcaer Ozturk, Anıl Delik · 2025 · Frontiers in Oncology
  51. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to Immunotherapy
    Jinyang Li, Ben Z. Stanger · 2020 · Cancer Research
  52. Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
    Kexun Zhou, Shuo Li, Yi Zhao, Ke Cheng · 2023 · Frontiers in Immunology
  53. Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
    Simer Jit Bains, Hanna Abrahamsson, Kjersti Flatmark, Svein Dueland, Knut Håkon Hole, Therese Seierstad, Kathrine Røe Redalen, Sebastian Meltzer, Anne Hansen Ree · 2019 · Cancer Immunology Immunotherapy
  54. Update on Emerging Therapies for Advanced Colorectal Cancer
    Olatunji Boladale Alese, Christina Sing-Ying Wu, William Joseph Chapin, Mark Bilinyi Ulanja, Binbin Zheng-Lin, Millicent Amankwah, Jennifer Rachel Eads · 2023 · American Society of Clinical Oncology Educational Book
  55. Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
    Janice M. Oh, Susan W. Kim, Carolyn Tsung, Eric William Kent, Arad Jain, Samantha M. Ruff, Hongji Zhang · 2025 · Frontiers in Immunology
  56. Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
    Yuan Zhuang, Chang Xin Liu, Jiaqing Liu, Guang Li · 2020 · OncoTargets and Therapy
  57. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
    April A. N. Rose, Susan M. Armstrong, David Hogg, Marcus Otho Butler, Samuel David Saibil, Diana Paola Arteaga, Thiago Pimentel Muniz, Deirdre Kelly, Danny Ghazarian, Ian F. G. King et al. · 2021 · Journal for ImmunoTherapy of Cancer
  58. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer
    Federica Pecci, Luca Cantini, Alessandro Bittoni, Edoardo Lenci, Alessio Lupi, Sonia Crocetti, Enrica Giglio, Riccardo Giampieri, Rossana Berardi · 2021 · Current Treatment Options in Oncology
  59. USP19 exacerbates lipogenesis and colorectal carcinogenesis by stabilizing ME1
    Yahui Zhu, Li Gu, Xi Lin, Xinyi Zhou, Bingjun Lu, Cheng Liu, Cao‐Qi Lei, Feng Zhou, Qiu Zhao, Edward V. Prochownik et al. · 2021 · Cell Reports
  60. YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation
    Pritam Sadhukhan, Mingxiao Feng, Emily J. Illingworth, Ido Sloma, Akira Ooki, Andrés Matoso, David Sidransky, Burles Avner Johnson, Luigi Marchionni, Fenna C.M. Sillé et al. · 2024 · Journal of Clinical Investigation
  61. Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
    Patrícia Dias Carvalho, Ana Luísa Machado, Flávia Martins, Raquel Seruca, Sérgia Velho · 2019 · Cancers
  62. How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC
    Li Chen, Xiaoying Jiang, Yuanheng Li, Qiqi Zhang, Qing Li, Xiaoyan Zhang, Meng Zhang, Qiongfang Yu, Dian Gao · 2022 · Clinical Immunology
  63. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
    Jesse Boumelha, Míriam Molina‐Arcas, Julian Downward · 2023 · Clinical Cancer Research
  64. Targeted modulation of myeloid-derived suppressor cells in the tumor microenvironment: Implications for cancer therapy
    Yafeng Qi, Liying Zhang, Yeyuan Liu, Yangyang Li, Yongqi Liu, Zhiming Zhang · 2024 · Biomedicine & Pharmacotherapy
  65. Targeting neutrophils for cancer therapy
    Jeff Kwak, A. McGarry Houghton · 2025 · Nature Reviews Drug Discovery
  66. Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer
    İbrahim Halil Şahin, Subir Goyal, Yoanna S Pumpalova, Mohamad Bassam Sonbol, Satya Das, Sigurdís Haraldsdóttir, Daniel H. Ahn, Kristen Keon Ciombor, Zhengjia Chen, Amber Draper et al. · 2021 · The Oncologist
  67. An Inflammatory Checkpoint Generated by IL1RN Splicing Offers Therapeutic Opportunity for KRAS -Mutant Intrahepatic Cholangiocarcinoma
    Mao Zhang, Yingying Huang, Jiaomeng Pan, Chen Sang, Youpei Lin, Liangqing Dong, Xia Shen, Yingcheng Charles Wu, Guohe Song, Shuyi Ji et al. · 2023 · Cancer Discovery
  68. Immunogenomic cancer evolution: A framework to understand cancer immunosuppression
    Shogo Kumagai, Yusaku Momoi, Hiroyoshi Nishikawa · 2025 · Science Immunology
  69. Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
    Yiru Zhou, Yeye Kuang, Chan Wang, Yijian Yu, Lijuan Pan, Xiaotong Hu · 2024 · International Journal of Biological Sciences
  70. QDPR deficiency drives immune suppression in pancreatic cancer
    Ji Liu, Xiaowei He, Shuang Deng, Sihan Zhao, Shaoping Zhang, Ziming Chen, Chunling Xue, Lingxing Zeng, Hongzhe Zhao, Yifan Zhou et al. · 2024 · Cell Metabolism
  71. Inhibition of DUSP18 impairs cholesterol biosynthesis and promotes anti-tumor immunity in colorectal cancer
    Xiaojun Zhou, Genxin Wang, Chenhui Tian, Lin Du, Edward V. Prochownik, Youjun Li · 2024 · Nature Communications
  72. Combined KRAS Inhibition and Immune Therapy Generates Durable Complete Responses in an Autochthonous PDAC Model
    Yonghong Liu, Jincheng Han, Wen‐Hao Hsu, Kyle A. LaBella, Pingna Deng, Xiaoying Shang, Paulino Tallón de Lara, Li Cai, Shan Jiang, Ronald Anthony DePinho · 2024 · Cancer Discovery
  73. CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis
    Qiuhua Lai, Qingyuan Li, Chengcheng He, Yuxin Fang, Simin Lin, Jianqun Cai, Jian Ping Ding, Qian Zhong, Yue Zhang, Changjie Wu et al. · 2020 · Aging
  74. What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
    Qingyi Wang, Bin Xie, Shuang Liu, Ying Shi, Yongguang Tao, Desheng Xiao, Wenxiang Wang · 2021 · Frontiers in Immunology
  75. MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC
    Derek A. Franklin, Joe T. Sharick, Paula I. González Ericsson, Violeta M. Sanchez, Phillip T. Dean, Susan R. Opalenik, Stefano Cairo, Jean‐Gabriel Judde, Michael T. Lewis, Jenny C. Chang et al. · 2020 · JCI Insight
  76. Genomic instability as a driver and suppressor of anti-tumor immunity
    Marta Requesens, Floris Foijer, Hans W. Nijman, Marco de Bruyn · 2024 · Frontiers in Immunology
  77. KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy
    Priyanka Uniyal, Vivek Kumar Kashyap, Tapan Behl, Deepak Parashar, Ravi Rawat · 2025 · Cancers
  78. Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression
    Kai Yin, Xueli Xia, Ke Rui, Tingting Wang, Shengjun Wang · 2020 · Frontiers in Oncology
  79. Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer
    Qi Xie, Xiaolin Liu, Rengyun Liu, Jingxuan Pan, Jing Liang · 2024 · Molecular Cancer
  80. Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages
    Takahiko Sato, Daisuke Sugiyama, Jun Koseki, Yasuhiro Kojima, Satomi Hattori, Kazuki Sone, Hitomi Nishinakamura, Tomohiro Ishikawa, Yuichi Ishikawa, Takuma Kato et al. · 2025 · JCI Insight
  81. Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
    Brandon M. Lehrich, Evan R. Delgado, Tyler M. Yasaka, Silvia Liu, Catherine Cao, Yuqing Liu, Mohammad Naser Taheri, Xiangnan Guan, Hartmut Koeppen, Sucha Singh et al. · 2025 · Nature Communications
  82. Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
    Jorien B.E. Janssen, Jan Paul Medema, Elske C. Gootjes, Daniele V. F. Tauriello, Henk M.W. Verheul · 2022 · Cancer Treatment Reviews
  83. Somatic 9p24.1 alterations in HPV – head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity
    Xin Zhao, Ezra E.W. Cohen, William N. William, Joy J. Bianchi, Jim P. Abraham, Daniel Magee, David B. Spetzler, Jorge Silvio Gutkind, Ludmil B. Alexandrov, Webster K. Cavenee et al. · 2022 · Proceedings of the National Academy of Sciences
  84. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis
    Jiayan Chen, Wanjun Lu, Mo Chen, Zijing Cai, Ping Zhan, Xin Liu, Suhua Zhu, Mingxiang Ye, Tangfeng Lv, Jiawen Lv et al. · 2024 · Therapeutic Advances in Medical Oncology
  85. IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin
    Yarong Guo, Jun Xu, Qiang Du, Yihe Yan, David A. Geller · 2021 · Translational Oncology
  86. Colorectal Cancer Immunotherapy: State of the Art and Future Directions
    Cornista, Alyssa Mauri, Giolito, Maria Virginia, Baker, Kristi, Hazime, Hajar, Dufait, Inès, Datta, Jashodeep, Khumukcham, Saratchandra Singh, De Ridder, Mark, Roper, Jatin, Abreu, Maria T. et al. · 2023 · Gastro Hep Advances
  87. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
    Rafael Rosell, Jordi Codony‐Servat, Jessica González, Mariacarmela Santarpía, Anisha S Jain, Chandan Shivamallu, Yu Wang, Ana A. Giménez-Capitán, Miguel Ángel Molina‐Vila, Jonas A. Nilsson et al. · 2023 · Critical Reviews in Oncology/Hematology
  88. Myeloid‑derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review)
    Wenjuan Zeng, Haohan Liu, Yuanhao Mao, Shihao Jiang, Yi Hao, Zitong Zhang, Menghui Wang, Zhen Zong · 2024 · International Journal of Oncology
  89. ImmunoAIzer: A Deep Learning-Based Computational Framework to Characterize Cell Distribution and Gene Mutation in Tumor Microenvironment
    Chang Bian, Yu Wang, Zhihao Lü, Yu An, Hanfan Wang, Lingxin Kong, Yang Du, Jie Tian · 2021 · Cancers
  90. IRF7 inhibits the Warburg effect via transcriptional suppression of PKM2 in osteosarcoma
    Zhikun Li, Mei Geng, Xiaojian Ye, Yunhan Ji, Yifan Li, Xiangyang Zhang, Wei Xu · 2021 · International Journal of Biological Sciences
  91. The Formation of NETs and Their Mechanism of Promoting Tumor Metastasis
    Jian Li, Jing Chen, Jing Sun, Kaichun Li · 2023 · Journal of Oncology
  92. Gene expression and methylation profiles identified CXCL3 and CXCL8 as key genes for diagnosis and prognosis of colon adenocarcinoma
    Qingqing Zhao, Chun Ling Jiang, Qian Gao, Yingying Zhang, Wang Guo, Xiaoping Chen, Shao‐Bin Wu, Jie Tang · 2019 · Journal of Cellular Physiology
  93. The role of myeloid‐derived suppressor cells in gastrointestinal cancer
    Cheng Cui, Penglin Lan, Li Fu · 2021 · 癌症：英文版
  94. KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic Ductal Adenocarcinoma and Other Adenocarcinomas
    Gu, Meichen, Gao, Yanli, Chang, Pengyu · 2021 · Cancers
  95. Oncogenic KRAS Drives Immune Suppression in Colorectal Cancer
    Kay Hänggi, Brian Ruffell · 2019 · Cancer Cell
  96. Clinically relevant fusion oncogenes: detection and practical implications
    Maxim Sorokin, Elizaveta Rabushko, Julian Markovich Rozenberg, Tharaa Mohammad, Aleksander Seryakov, Marina I Sekacheva, Anton A. Buzdin · 2022 · Therapeutic Advances in Medical Oncology
  97. Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer
    Yuan Jiang, Yueyuan Zheng, Yuan‐Wei Zhang, Shuai Kong, Jinxiu Dong, Fei Wang, Benjamin Ziman, Sigal Gery, Jia‐Jie Hao, Dan Zhou et al. · 2024 · Nature Communications
  98. Response and Mechanisms of Resistance to Larotrectinib and Selitrectinib in Metastatic Undifferentiated Sarcoma Harboring Oncogenic Fusion of NTRK1
    Matthew L. Hemming, Michael Jason Nathenson, Jia‐Ren Lin, Shaolin Mei, Ziming Du, Karan Malik, Adrián Mariño‐Enríquez, Jyothi Priya Jagannathan, Peter Karl Sorger, Monica M. Bertagnolli et al. · 2020 · JCO Precision Oncology
  99. Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy
    Houhui Shi, Kai Li, Yanghong Ni, Xiao Liang, Xia Zhao · 2021 · Frontiers in Cell and Developmental Biology
  100. CXCL3: A key player in tumor microenvironment and inflammatory diseases
    Yuxuan Bao, Chang Tong, Xiangyang Xiong · 2024 · Life Sciences